Novo Nordisk announced its decision to partner with digital health providers to streamline access to Wegovy after a U.S. shortage has eased. And Novo will offer direct-to-consumer access via its ...

Shares of Hims & Hers closed up 23% on Tuesday, while Novo Nordisk's stock closed up 4%. The Danish drugmaker is racing to capture more patients now that many compounding pharmacies are legally ...

Shares of online pharmacy Hims & Hers surged after it struck a deal with Danish obesity drug maker Novo Nordisk to sell its Wegovy drug in the U.S. In a joint venture with Novo Nordisk ...

Him & Hers Health and Novo ... disease, and doing that more affordably," said Dave Moore, executive vice president of U.S. operations and global business development and president of Novo Nordisk.

You can reach Elaine on Signal at elaineywchen.70. BridgeBio’s recently approved heart drug brought in $36.7 million in sales in the first quarter, blowing past expectations as the biotech ...

That partnership will see Hims & Hers offer Novo Nordisk’s weight-loss drug Wegovy through its platform. Here’s what you need to know. Hims & Hers will offer weight-loss drug Wegovy Hims ...

SANTA FE, N.M. (AP) — The main cause of Gene Hackman's death was heart disease, but he was also in the advanced stages of Alzheimer's disease and likely had not eaten for a long time ...

In the United States, about 40,000 babies are born with a heart defect each year, according to the Centers for Disease Control and Prevention. Of those, 1 in 4 have a critical heart defect. These ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...

Ozempic is an injectable prescription medication used to manage blood sugar in people with type 2 diabetes and lower the risk of heart events like heart attack and stroke in adults with both type 2 ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.